Positive recommendation on sensor-based glucose monitoring devices by Danish Health Technology Council

The Danish Health Technology Council (Behandlingsrådet) launched in 2021 aimed to support the greater use of cost-effective technologies in the healthcare system through recommendations to regions and hospitals. The recommendations are not legally binding; however, it is expected that they will likely be followed and will impact funding decisions.

The Council develops two types of reports: evaluations and major analyses (større analyser). In both cases, there is a staged process: proposal, evaluation or analysis, decision, and implementation. However, there are some differences:

• The Council annually develops 2-3 ‘major analyses’ on the fundamental topics (e.g., treatment regimens, approaches to the organization of treatments) proposed by hospitals or regions (not industry);
• The Council annually prepares up to 15-25 ‘evaluations’ on marketed medical devices and health technologies proposed by any stakeholder (including industry).

In March 2023, the Danish Health Technology Council completed a major analysis started in June 2022 on patient-centered diabetes technology.

The Council recommended that sensor-based glucose monitoring devices with alarms be offered to all adult patients with type 1 diabetes. It was concluded that the use of technology benefits all four perspectives that the Council assesses: clinical effectiveness and safety, the patient perspective, the organizational perspective, and the health economy.

The recommendations apply to public hospitals. The Council notes that implementing the recommendations will promote the transfer of funds for procuring sensor-based monitoring devices.

See more information in Danish here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.